Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology

The therapeutic armamentarium for the management of Crohn's disease (CD) is rapidly expanding. Several biologic therapies (e.g. infliximab, adalimumab, vedolizumab, and ustekinumab) have been regulatory approved, and there is considerable practice variability in the treatment of patients with C...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease 2023-06, Vol.55 (6), p.695-703
Main Authors: Bonovas, Stefanos, Piovani, Daniele, Pansieri, Claudia, Macaluso, Fabio Salvatore, Orlando, Ambrogio, Festa, Stefano, Papi, Claudio, Pugliese, Daniela, Armuzzi, Alessandro
Format: Article
Language:English
Subjects:
Adalimumab - therapeutic use
Adult
Biological Products - therapeutic use
Crohn Disease - drug therapy
Crohn's disease
GRADE
Guidelines
Humans
Infliximab - therapeutic use
Ustekinumab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The therapeutic armamentarium for the management of Crohn's disease (CD) is rapidly expanding. Several biologic therapies (e.g. infliximab, adalimumab, vedolizumab, and ustekinumab) have been regulatory approved, and there is considerable practice variability in the treatment of patients with CD. This technical review systematically searched and identified the current evidence, synthesized it using meta-analytic methodology, appraised its quality, and concisely presented it, thus forming the basis for developing clinical practice recommendations on the use of biologic treatments in adult patients with CD.
ISSN:1590-8658
1878-3562
DOI:10.1016/j.dld.2023.02.019